| Identification | Back Directory | [Name]
(S)-N-[5-[[6-[2-[7,7-Dimethyl-1-oxo-3,4,7,8-tetrahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2(6H)-yl]-3-(hydroxymethyl)-4-pyridyl]-4-methyl-3-oxo-3,4-dihydro-2-pyrazinyl]amino]-2-[2-methyl-4-(tetrahydro-2H-pyran-4-yl)piperazin-1-yl]phenyl]acrylamide | [CAS]
2485861-07-0 | [Synonyms]
Rocbrutinib
(S)-N-[5-[[6-[2-[7,7-Dimethyl-1-oxo-3,4,7,8-tetrahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2(6H)-yl]-3-(hydroxymethyl)-4-pyridyl]-4-methyl-3-oxo-3,4-dihydro-2-pyrazinyl]amino]-2-[2-methyl-4-(tetrahydro-2H-pyran-4-yl)piperazin-1-yl]phenyl]acrylamide |
| Hazard Information | Back Directory | [Uses]
Rocbrutinib is a Bruton's tyrosine kinase inhibitor with antineoplastic effect[1]. | [References]
[1] Chen Yi, et al. Preparation of pyrrolopyrazines and related heterocycles as inhibitors of BTK and mutants thereof for the treatment of neoplastic, autoimmune and inflammatory disorders. World Intellectual Property Organization, WO2020176403 A1 2020-09-03. |
|
|